Project coordinator

Certest is a Spanish biotech company specialised in immunochemistry and molecular biology. In the recent years, the company has established a robust technological platform for the development of advanced RNA-based therapies encompassing RNA design, synthesis, and delivery, utilizing our proprietary lipids and formulations.

Over the past 30 years, the “Grupo de Genética de Micobacterias” from the University of Zaragoza has gained ample experience in the discovery, construction, characterisation and preclinical, good-manufacturing practices (GMP) and clinical development of the live tuberculosis vaccine MTBVAC, which is now entered Phase 3 efficacy evaluation. MTBVAC will be also assayed in this project. In addition to its expertise, the University of Zaragoza has the appropriate biosafety facilities (NCB3) to conduct the efficacy studies against Tuberculosis of vaccine candidates in animal models.

NanoBioCel group from UPV/EHU has extensive experience in the formulation and characterisation of pharmaceutical compositions, in particular, formulations for pulmonary administration. This group has at its disposal state-of-the-art laboratories and equipment belonging to U10 Drug Formulation de Nanbiosis. This Unit is one of the Singular Scientific and Technological infrastructures (ICTS) recognised by the Spanish Ministry of Science and Innovation.